MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Survival

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Oncologist 2017 February 10 [Epub ahead of print] [Link] Wang X1, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Kishor Ganti A, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H Abstract PURPOSE: The aim of this study was to investigate whether progression-free survival (PFS) can be considered […]

Comments Off on Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Oncotarget 2017 January 18 [Epub ahead of print] [Link] Pei D1, Li Y, Liu X, Yan S, Guo X, Xu X, Guo X Abstract Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. […]

Comments Off on Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues

Journal of Molecular Diagnostics 2017 January [Epub 2016 Nov 15] [Link] De Rienzo A, Cook RW, Wilkinson J, Gustafson CE, Amin W, Johnson CE, Oelschlager KM, Maetzold DJ, Stone JF, Feldman MD, Becich MJ, Yeap BY, Richards WG, Bueno R Abstract A molecular test performed using fresh-frozen tissue was proposed for use in the prognosis […]

Comments Off on Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues

Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

European Journal of of Radiology [2017 January] [Link] Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T Abstract PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most […]

Comments Off on Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

New therapeutic strategies for malignant pleural mesothelioma

Biochemical Pharmacology 2017 January [Epub ahead of print] [Link] Bonelli MA, Fumarola C, La Monica S, Alfieri R Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which most patients are diagnosed and the […]

Comments Off on New therapeutic strategies for malignant pleural mesothelioma

Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

Pathology Oncology Research 2017 January 4 [Epub ahead of print] [Link] Plönes T, Fischer M, Höhne K, Sato H, Müller-Quernheim J, Zissel G Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface of the pleura and is associated with a history of asbestos exposure. The tumor is characterized by […]

Comments Off on Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma

European Journal of Radiology 2017 January [Epub 2016 November] [Link] Kitajima K, Doi H, Kuribayashi K, Hashimoto M, Tsuchitani T, Tanooka M, Fukushima K, Nakano T, Hasegawa S, Hirota S Abstract PURPOSE: To investigate the relationships between pretreatment volume-based quantitative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters and overall survival (OS) in patients with […]

Comments Off on Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

JAMA Oncology 2017 January [Link] Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, […]

Comments Off on Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% malignant peritoneal mesotheliomas

Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2016 December 27 [Epub ahead of print] [Link] Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, […]

Comments Off on BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% malignant peritoneal mesotheliomas